Clinical trial
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head…
NCT00180921 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Unknown status
Key facts
| NCT number | NCT00180921 |
|---|---|
| Title | Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck |
| Official title | Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of the Head and Neck, Carcinoma, Adenoid Cystic |
| Intervention type | Drug |
| Interventions | Imatinib |
| Enrollment | 30 |
| Start date | Jul 1, 2004 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 26, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: